A detailed history of Benchmark Investment Advisors LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Benchmark Investment Advisors LLC holds 249 shares of LLY stock, worth $186,730. This represents 0.16% of its overall portfolio holdings.

Number of Shares
249
Previous 249 -0.0%
Holding current value
$186,730
Previous $225,000 2.22%
% of portfolio
0.16%
Previous 0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$724.87 - $909.04 $180,492 - $226,350
249 New
249 $225,000
Q4 2023

Feb 13, 2024

BUY
$525.19 - $619.13 $683,797 - $806,107
1,302 New
1,302 $758,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $713B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Benchmark Investment Advisors LLC Portfolio

Follow Benchmark Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benchmark Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Benchmark Investment Advisors LLC with notifications on news.